STO · MNTC.ST
Mentice AB (publ)
SEK 15.50-SEK 0.50 (-3.13%)
Mentice AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.21% below the high.
Loading market information…
STO · LIPUM.ST · SEK
Stock price, earnings
Quote as of Mar 18, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Lipum AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 28.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lipum AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on pioneering the discovery and development of therapeutic solutions for long-term inflammatory conditions. The company's primary therapeutic asset, SOL-116, is a humanized antibody currently in the late preclinical stage, designed to treat pediatric rheumatism and adult rheumatoid arthritis. To facilitate the advancement of SOL-116 into clinical trials, Lipum has established a collaboration with Pelago Bioscience AB to meticulously monitor drug targets. Founded in 2010, the company's operations are headquartered in Umeå, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:58 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 15.50-SEK 0.50 (-3.13%)
Mentice AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 18.21% below the high.
SEK 1.19+SEK 0.04 (+3.66%)
Isofol Medical AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 4.96% below the high.
SEK 3.17+SEK 0.12 (+3.93%)
Bio-Works Technologies AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 36.35% below the high.
SEK 2.12+SEK 0.07 (+3.41%)
IRLAB Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 23.74% below the high.
SEK 2.09+SEK 0.04 (+1.95%)
Initiator Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 42.74% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 0.24+SEK 0.01 (+2.13%)
KDventures AB’s quoted price sits in the lower half of its reported 52-week range, 82.14% below the high.
SEK 0.81-SEK 0.08 (-8.58%)
Enorama Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 71.68% below the high.
